MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015)
Conditions:   Arteriosclerosis;   Hypercholesterolaemia Interventions:   Drug: MK-0616;   Drug: Placebo Sponsor:   Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 24, 2023 Category: Research Source Type: clinical trials

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
Conditions:   Dyslipidemias;   Hypercholesterolemia;   Familial Hypercholesterolemia;   ASCVD;   High Cholesterol Interventions:   Combination Product: Combination Therapy;   Drug: Monotherapy obicetrapib;   Drug: Monotherapy ezetimibe;   Other: Combination Therapy placebo;   Other: Obicetrapib Placebo;   Other: Ezetimibe Placebo Sponsor:   NewAmsterdam Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials